Steven Cohen Oric Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.41 - $9.43 $2.82 Million - $4.91 Million	521,142 New	521,142 $4.79 Million
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $57,331 - $90,841	-13,458 Reduced 70.46%	5,642 $32,000
Q4 2022 Feb 14, 2023	BUY	$2.41 - $5.89 $21,931 - $53,599	9,100 Added 91.0%	19,100 $112,000
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $31,500 - $52,400	10,000 New	10,000 $32,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $21,060 - $55,146	-7,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $35,412 - $125,580	7,800 New	7,800 $42,000
Q4 2021 Feb 14, 2022	SELL	$12.01 - $20.3 $4.01 Million - $6.78 Million	-333,782 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$15.9 - $25.22 $9.7 Million - $15.4 Million	-610,219 Reduced 64.64%	333,782 $6.98 Million
Q2 2021 Aug 16, 2021	SELL	$17.37 - $25.34 $5.93 Million - $8.66 Million	-341,646 Reduced 26.57%	944,001 $16.7 Million
Q1 2021 May 17, 2021	BUY	$23.67 - $36.85 $30.4 Million - $47.4 Million	1,285,647 New	1,285,647 $31.5 Million

112

63.1M

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $406M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.